NCT07569016Recruiting
BIS-Guided Sedation Versus Standard Clinical Sedation During Elective Electrical Cardioversion for Atrial Fibrillation
Bispectral Index-Guided Sedation Versus Standard Clinical Assessment-Guided Sedation During Elective Electrical Cardioversion for Atrial Fibrillation: A Prospective, Single-Center, Randomized Controlled, Assessor-Blinded Trial
Source: ClinicalTrials.gov · Last updated 15 May 2026
Brief summary (registry, in English)
Electrical cardioversion (ECV) is a standard procedure used to restore normal heart rhythm in patients with atrial fibrillation (AF) by delivering a brief electrical shock to the heart. Because the procedure is painful and distressing, patients receive sedation - a controlled state of reduced consciousness - using short-acting intravenous medications. However, the optimal depth of sedation for ECV has not been well defined: too deep may cause breathing problems and low blood pressure, while too light may result in pain, awareness, or patient movement during the shock. Bispectral index (BIS) monitoring is a non-invasive technology that continuously measures brain activity using an EEG sensor placed on the forehead, generating a numerical score from 0 (no brain activity) to 100 (fully awake). BIS scores between 61 and 80 correspond to moderate sedation, which preliminary observations suggest may be sufficient for ECV without the risks associated with deeper sedation. This randomized controlled trial will compare two approaches to sedation monitoring during elective ECV for AF: * Group 1 (BIS Group): Sedation is guided by BIS monitoring, targeting a score of 61-80. * Group 2 (Control Group): Sedation is guided by standard clinical assessment (loss of response to verbal commands and eyelash reflex), with BIS recorded but not visible to the treating team. Both groups will receive the same medications (propofol and fentanyl). The primary outcome is how quickly patients recover after the procedure, measured by the Modified Aldrete Score - a standard clinical recovery assessment tool. Secondary outcomes include patient and physician satisfaction, procedural pain, risk of awareness during the procedure, cardioversion success rate, hemodynamic stability, and complication rates. The trial will enroll 60 adult patients at Istanbul University-Cerrahpasa Cardiology Institute. Findings are expected to provide evidence-based guidance for standardizing sedation protocols during ECV.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 12 Apr 2026
- Start date
- 13 Apr 2026
- Primary completion date
- 15 Jun 2026
- Lead sponsor
- Istanbul University - Cerrahpasa
- Diseases
- Atrial fibrillation
- NCT number
- NCT07569016
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 13 Apr 2026 to the primary completion date, 15 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Severe obstructive sleep apnea requiring CPAP or BiPAP therapy
- Prior participation in this trial
Other illness
- Known allergy or contraindication to propofol or fentanyl, or their excipients (soy, egg)
- Decompensated heart failure (NYHA functional class IV)
- Baseline oxygen saturation \<94% or active chronic obstructive pulmonary disease
- Active psychiatric illness or cognitive impairment precluding questionnaire completion
Lab values
- Severe hepatic impairment (transaminases \>3× upper limit of normal) or severe renal impairment (eGFR \<30 mL/min/1.73m²)
Other
- Hemodynamic instability (systolic blood pressure \<90 mmHg or symptomatic hypotension)
- Anticipated difficult airway (modified Mallampati classification class III or IV)
- Pregnancy or breastfeeding
- Alcohol or substance use within the preceding 24 hours
Who the study is looking for
- Age ≥18 years
- Documented atrial fibrillation with indication for elective electrical cardioversion
- American Society of Anesthesiologists (ASA) physical status class I, II, or III
- Left ventricular ejection fraction ≥30% on echocardiography
- Adequate anticoagulation: INR ≥2.0, OR ≥3 weeks of therapeutic anticoagulation, OR absence of left atrial thrombus confirmed by transesophageal echocardiography
- Ability and willingness to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Istanbul University-Cerrahpaşa, Cardiology Institute Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.